Stockscreener 앱 받기
6.48
0.15%
0.01
전일 마감가:
$6.47
열려 있는:
$6.51
하루 거래량:
65,689
Relative Volume:
0.54
시가총액:
$687.10M
수익:
$117.05M
순이익/손실:
$-3.71M
주가수익비율:
-83.18
EPS:
-0.0779
순현금흐름:
$1.67M
1주 성능:
-4.14%
1개월 성능:
-3.14%
6개월 성능:
-19.20%
1년 성능:
-26.94%
1일 변동 폭
$6.41
$6.65
1주일 범위
$6.442
$7.09
52주 변동 폭
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 284-0115
주소
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.48 | 687.10M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
507.97 | 128.75B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.41 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.91 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.65 | 53.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.77 | 42.28B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesTax Rate Impact - dars.gov.et
Gyre Therapeutics stock posts double digit 12 month gain as investors watch pipeline progress - AD HOC NEWS
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones - AD HOC NEWS
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Detailed Stock Data - The Chronicle-Journal
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal
Gyre Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rise 6.57%EBITDA Margin Trends - www.dars.gov.et
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - marketscreener.com
Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - The Globe and Mail
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - TipRanks
Gyre updates corporate presentation, outlines China-driven R&D and F351 regulatory progress - TradingView
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail
Gyre Therapeutics unveils capital-efficient global development strategy - TipRanks
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers - TradingView
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Palomar (PLMR) Results Check: EPS Clears the Reported Estimate in the Latest Session; Market Response: Shares Move 0.92% LowerMargin Improvement Report - careplusvn.com
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceMedian Line - siam.in
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Surprise Score - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Gyre Therapeutics Inc 주식 (GYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
Jun 18 '26 |
Sale |
6.35 |
3,000 |
19,050 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Sale |
6.17 |
2,800 |
17,276 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 11 '26 |
Option Exercise |
0.75 |
2,800 |
2,100 |
702,800 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.21 |
6,418 |
39,856 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Sale |
6.24 |
5,000 |
31,200 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 10 '26 |
Option Exercise |
0.75 |
6,418 |
4,814 |
706,418 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.14 |
14,500 |
89,030 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Sale |
6.15 |
3,000 |
18,450 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
14,500 |
10,875 |
714,500 |
| Ye Weiguo | Chief Operating Officer |
Jun 09 '26 |
Option Exercise |
0.75 |
3,000 |
2,250 |
703,000 |
0.64%
1.66%
자본화:
|
볼륨(24시간):